137 related articles for article (PubMed ID: 34211841)
1. Fenretinide Acts as Potent Radiosensitizer for Treatment of Rhabdomyosarcoma Cells.
Brack E; Bender S; Wachtel M; Pruschy M; Schäfer BW
Front Oncol; 2021; 11():664462. PubMed ID: 34211841
[TBL] [Abstract][Full Text] [Related]
2. Fenretinide induces a new form of dynamin-dependent cell death in pediatric sarcoma.
Brack E; Wachtel M; Wolf A; Kaech A; Ziegler U; Schäfer BW
Cell Death Differ; 2020 Aug; 27(8):2500-2516. PubMed ID: 32144381
[TBL] [Abstract][Full Text] [Related]
3. Fenretinide (4-HPR) Targets Caspase-9, ERK 1/2 and the Wnt3a/β-Catenin Pathway in Medulloblastoma Cells and Medulloblastoma Cell Spheroids.
Bassani B; Bartolini D; Pagani A; Principi E; Zollo M; Noonan DM; Albini A; Bruno A
PLoS One; 2016; 11(7):e0154111. PubMed ID: 27367907
[TBL] [Abstract][Full Text] [Related]
4. Modulating the dose-rate differently affects the responsiveness of human epithelial prostate- and mesenchymal rhabdomyosarcoma-cancer cell line to radiation.
Petragnano F; Pietrantoni I; Di Nisio V; Fasciani I; Del Fattore A; Capalbo C; Cheleschi S; Tini P; Orelli S; Codenotti S; Mazzei MA; D'Ermo G; Pannitteri G; Tombolini M; De Cesaris P; Riccioli A; Filippini A; Milazzo L; Vulcano F; Fanzani A; Maggio R; Marampon F; Tombolini V
Int J Radiat Biol; 2020 Jun; 96(6):823-835. PubMed ID: 32149569
[No Abstract] [Full Text] [Related]
5. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model.
Dobson CC; Naing T; Beug ST; Faye MD; Chabot J; St-Jean M; Walker DE; LaCasse EC; Stojdl DF; Korneluk RG; Holcik M
Oncotarget; 2017 Jan; 8(2):3495-3508. PubMed ID: 27966453
[TBL] [Abstract][Full Text] [Related]
7. Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death.
Ommer J; Selfe JL; Wachtel M; O'Brien EM; Laubscher D; Roemmele M; Kasper S; Delattre O; Surdez D; Petts G; Kelsey A; Shipley J; Schäfer BW
Cancer Res; 2020 Feb; 80(4):832-842. PubMed ID: 31888889
[TBL] [Abstract][Full Text] [Related]
8. OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cells.
Tomoyasu C; Kikuchi K; Kaneda D; Yagyu S; Miyachi M; Tsuchiya K; Iehara T; Sakai T; Hosoi H
Oncol Rep; 2019 Jan; 41(1):643-649. PubMed ID: 30365145
[TBL] [Abstract][Full Text] [Related]
9. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of fenretinide (4-HPR)-induced cell death.
Wu JM; DiPietrantonio AM; Hsieh TC
Apoptosis; 2001 Oct; 6(5):377-88. PubMed ID: 11483862
[TBL] [Abstract][Full Text] [Related]
11. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
[TBL] [Abstract][Full Text] [Related]
12. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
Stehle A; Hugle M; Fulda S
Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
[TBL] [Abstract][Full Text] [Related]
13. Fenretinide targets the side population in myeloma cell line NCI-H929 and potentiates the efficacy of antimyeloma with bortezomib and dexamethasone regimen.
Yan W; Du J; Du Y; Pu H; Liu S; He J; Zhang J; Hou J
Leuk Res; 2016 Dec; 51():32-40. PubMed ID: 27821288
[TBL] [Abstract][Full Text] [Related]
14. Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies.
Makena MR; Koneru B; Nguyen TH; Kang MH; Reynolds CP
Mol Cancer Ther; 2017 Apr; 16(4):649-661. PubMed ID: 28119491
[TBL] [Abstract][Full Text] [Related]
15. Graphene Quantum Dots for Radiotherapy.
Ruan J; Wang Y; Li F; Jia R; Zhou G; Shao C; Zhu L; Cui M; Yang DP; Ge S
ACS Appl Mater Interfaces; 2018 May; 10(17):14342-14355. PubMed ID: 29542912
[TBL] [Abstract][Full Text] [Related]
16. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
[TBL] [Abstract][Full Text] [Related]
17. Luteolin acts as a radiosensitizer in non‑small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade.
Cho HJ; Ahn KC; Choi JY; Hwang SG; Kim WJ; Um HD; Park JK
Int J Oncol; 2015 Mar; 46(3):1149-58. PubMed ID: 25586525
[TBL] [Abstract][Full Text] [Related]
18. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
[TBL] [Abstract][Full Text] [Related]
19. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
[TBL] [Abstract][Full Text] [Related]
20. Niclosamide enhances ROS-mediated cell death through c-Jun activation.
Lee SL; Son AR; Ahn J; Song JY
Biomed Pharmacother; 2014 Jun; 68(5):619-24. PubMed ID: 24750999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
